Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.
Endovascular Engineering is a preclinical stage company focused on developing innovative mechanical thrombectomy solutions aimed at addressing peripheral vascular conditions. The company specializes in creating and implementing advanced clot removal technologies specifically designed for venous thromboembolism, which includes treatment for significant health issues such as pulmonary embolism and deep vein thrombosis. By equipping healthcare professionals with effective medical tools, Endovascular Engineering aims to enhance the management of these critical conditions and improve patient outcomes.
Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.
Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.
Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.
Developer of a secure collaboration platform designed to create secure data access to support impactful algorithm validation and development. The company's platform supports end-to-end data and algorithm encryption that ensures data security, it uses primary data from the source rather than synthetic or de-identified data, eliminates the risk of data exfiltration and interrogation of the algorithm IP from insiders and third parties, and acts as the middleman and matchmaker between data stewards and algorithm developers, helping healthcare organizations in keeping their data secure in their private cloud infrastructure.
Surgical Safety Technologies specializes in providing data-driven artificial intelligence technology to hospitals, aimed at enhancing surgical safety. The company’s platform offers an objective assessment of both technical and non-technical skills of surgeons, utilizing academically validated frameworks. By delivering descriptive, predictive, and prescriptive insights, the platform supports data-driven clinical and operational decisions, ultimately improving surgical quality and patient safety in healthcare settings.
Wave Life is a new kind of mental health platform that makes emotional wellbeing an achievable part of everyday life. The app's mental health coach and toolkit empower users to live each day with intention. Mental health coaching helps to build self-awareness, discover values, and cope with stress.
ABK Biomedical combines the clinical market with biomaterials. It specializes in improving treatment options for patients with hypervascular tumors. The company is dedicated to transforming an interventional radiology procedure called embolization.
Sensorium Therapeutics is a drug discovery platform based in Boston, Massachusetts, that focuses on developing novel FDA-approved psychoactive medicines. Founded in 2021, the company utilizes an artificial intelligence product engine to discover and develop drugs targeting central nervous system diseases. By integrating historical human efficacy data from natural compounds, Sensorium Therapeutics aims to create new medicines characterized by innovative pharmacology and improved clinical success rates. This approach enables pharmaceutical companies to enhance their drug development processes effectively.
RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.
Endovascular Engineering is a preclinical stage company focused on developing innovative mechanical thrombectomy solutions aimed at addressing peripheral vascular conditions. The company specializes in creating and implementing advanced clot removal technologies specifically designed for venous thromboembolism, which includes treatment for significant health issues such as pulmonary embolism and deep vein thrombosis. By equipping healthcare professionals with effective medical tools, Endovascular Engineering aims to enhance the management of these critical conditions and improve patient outcomes.
Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.
Reimagine Care is a healthcare company focused on enhancing community-based oncology care through technology-enabled services. Established in 2020 and based in Nashville, Tennessee, the company seeks to improve the affordability, accessibility, and patient-centricity of cancer care. By collaborating with healthcare systems and independent oncology practices, Reimagine Care supports value-based oncology care delivery. Their approach involves providing the necessary personnel, processes, and a comprehensive technology platform that facilitates the effective and scalable delivery of high-quality cancer care at various locations, including patients' homes. This model aims to enable patients to receive treatment and supportive care in a more convenient and cost-effective manner.
Access Optics is able to combine innovating manufacturing engineering, process development, and optical fabrication with advanced coating technology. The pioneering product development and advanced materials solutions have fostered breakthrough products for leading OEMs in endoscopy, dermatology, aerospace, and chromatography.
CryOSA is a medical device company focused on developing innovative treatments for obstructive sleep apnea. The company creates devices aimed at assisting patients with sleep-disordered breathing, particularly those experiencing moderate to severe forms of this condition. By addressing the challenges associated with obstructive sleep apnea, CryOSA seeks to improve the quality of life for individuals affected by this disorder.
RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.
Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.
Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.
Nirogy Therapeutics is a biotechnology company focused on developing innovative small molecules that target cellular transporters to address chronic diseases, including cancer and autoimmune disorders. The company employs a transporter target platform that integrates transporter biology, structural biology, and computational chemistry to understand the underlying mechanisms of these diseases. This approach guides the design and development of new drugs while also informing strategies for patient selection. By advancing small molecules aimed at disrupting metabolic and immune mechanisms within the tumor microenvironment, Nirogy Therapeutics aims to address significant unmet medical needs in oncology and inflammation.
KelaHealth, Inc. is a company that specializes in developing clinical decision support software tailored for surgical care. Founded in 2016 and based in San Francisco, California, KelaHealth's platform utilizes predictive analytics to identify potential surgical complications and risks, offering recommendations to mitigate these issues. By harnessing patient data, the platform aims to enhance the quality of surgical care and operational efficiency. It provides patient-specific insights and suggested interventions at critical decision points, creating a learning ecosystem that fosters continuous improvement in surgical outcomes. Additionally, KelaHealth's technology helps standardize practices among surgeons and addresses the administrative and regulatory requirements for quality compliance in surgical operations, ultimately assisting physicians and hospital administrators in better assessing patient risk and enhancing surgical quality.
KelaHealth, Inc. is a company that specializes in developing clinical decision support software tailored for surgical care. Founded in 2016 and based in San Francisco, California, KelaHealth's platform utilizes predictive analytics to identify potential surgical complications and risks, offering recommendations to mitigate these issues. By harnessing patient data, the platform aims to enhance the quality of surgical care and operational efficiency. It provides patient-specific insights and suggested interventions at critical decision points, creating a learning ecosystem that fosters continuous improvement in surgical outcomes. Additionally, KelaHealth's technology helps standardize practices among surgeons and addresses the administrative and regulatory requirements for quality compliance in surgical operations, ultimately assisting physicians and hospital administrators in better assessing patient risk and enhancing surgical quality.
Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2019. The company is dedicated to developing innovative disease-modifying therapeutics aimed at restoring cellular balance in patients suffering from neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. Libra Therapeutics focuses on small molecule drugs that enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Through its distinct molecular approaches, the company aims to address the cellular imbalances that characterize these debilitating conditions, thereby providing potential new treatment options for affected individuals.
CryOSA is a medical device company focused on developing innovative treatments for obstructive sleep apnea. The company creates devices aimed at assisting patients with sleep-disordered breathing, particularly those experiencing moderate to severe forms of this condition. By addressing the challenges associated with obstructive sleep apnea, CryOSA seeks to improve the quality of life for individuals affected by this disorder.
Glyscend Therapeutics is focused on developing innovative treatments for type 2 diabetes, drawing inspiration from the metabolic benefits observed in bariatric surgery. The company has created a non-invasive, orally ingestible intestinal coating designed to replicate the effects of surgery by preventing stimulation of the duodenal mucosa and inhibiting crucial neurohormonal pathways in the proximal gut. This novel approach aims to provide patients with effective glucose control while minimizing side effects such as weight gain and hypoglycemia. Glyscend also seeks to equip endocrinologists and primary care physicians with advanced tools to treat diabetes more effectively, rather than merely managing the condition. Founded in 2014 by Ashish Nimgaonkar, Michael Parlato, and Pratik Patel, Glyscend is committed to enhancing the care pathway for individuals living with type 2 diabetes.
BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.
Remedy provides an on-demand urgent and primary care service focusing on innovative delivery of care. Remedy delivers medical care in the form of 24/7 telemedicine and nurse access, lab visits, and house calls, for individual patients and large employer clients, enabling patients to get quality doorstep treatment at an affordable price. Remedy was founded in 2015 and is based in Austin, Texas.
Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.
Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.
Farapulse commercialize an innovative collection of catheter-based tools used to treat atrial fibrillation. Farapulse are working to make atrial fibrillation ablation safer, faster, more accessible, and less expensive for millions of people.
Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.
CryOSA is a medical device company focused on developing innovative treatments for obstructive sleep apnea. The company creates devices aimed at assisting patients with sleep-disordered breathing, particularly those experiencing moderate to severe forms of this condition. By addressing the challenges associated with obstructive sleep apnea, CryOSA seeks to improve the quality of life for individuals affected by this disorder.
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.
Millipede develops a catheter-based solution to treat mitral and tricuspid regurgitation, restoring health and expanding options for physicians, and global patients.
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
Lumos Pharma, based in Austin, Texas, is an early-stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency. It was founded in 2014 and is headquartered in Austin, Texas.
Farapulse commercialize an innovative collection of catheter-based tools used to treat atrial fibrillation. Farapulse are working to make atrial fibrillation ablation safer, faster, more accessible, and less expensive for millions of people.
Farapulse commercialize an innovative collection of catheter-based tools used to treat atrial fibrillation. Farapulse are working to make atrial fibrillation ablation safer, faster, more accessible, and less expensive for millions of people.
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.
BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.
TVA Medical, Inc. is a medical device company based in Austin, Texas, focused on developing catheter-based solutions for end-stage renal disease and peripheral vascular diseases. Founded in 2009, the company specializes in innovative, minimally invasive therapies, notably through its everlinQ endoAVF system. This system facilitates the creation of an arteriovenous fistula using an endovascular approach, allowing for hemodialysis in patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. TVA Medical operates as a subsidiary of Becton, Dickinson and Company and has received funding from Santé Ventures.
Terapio Corporation is a biopharmaceutical company founded in 2005 and based in Austin, Texas. The company specializes in developing therapeutics that utilize the transport protein RLIP76, which plays a crucial role in moving free-radical toxins out of cells, thereby preventing significant cellular damage. Terapio's pipeline includes therapies that enhance the availability of RLIP76 in normal cells, improving their ability to combat toxins from various sources, including chemical exposure and radiation. The therapeutics are designed as medical countermeasures, providing prophylactic and post-exposure treatment options for civilian, military, and first responder populations facing chemical and radiation threats.
Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.
Lyric is a clinical-stage company developing novel gastrointestinal therapeutics for unmet medical needs in the hospital setting. It was founded in 2013 and is headquartered in San Francisco, California.
ChanRx Corp. intends to develop and market small molecule pharmaceuticals to treat atrial fibrillation, a common arrhythmia that can cause heart attacks and strokes. The company was founded in 2008 and is based in Cleveland, Ohio.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.
Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.
Renascent Foundation offers evidence-based, trauma-informed care that addresses drug and alcohol addiction and concurrent mental health issues. They offer specialized addiction support programs for individuals, families, children, workplaces, organizations, and communities impacted by drug and alcohol addictions.
Lumos Pharma, based in Austin, Texas, is an early-stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency. It was founded in 2014 and is headquartered in Austin, Texas.
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.
Ketra specializes in high-performance LED lighting and integrated control systems designed for both high-end residential and commercial environments. The company offers a complete range of lighting components, including light fixtures, controls, and software, all manufactured in-house to ensure compatibility and cohesion. This integrated approach facilitates streamlined installation and user-friendly operation. Ketra's innovative technologies focus on delivering natural light experiences that enhance well-being, productivity, and overall quality of life. By providing advanced systems that balance color stability and uniform intensity, Ketra aims to create healthier and happier living and working spaces.
Guided Interventions is a Cleveland-based medical device startup focused on developing innovative wire-based medical devices aimed at enhancing the efficacy and safety of interventional procedures. Led by CEO Dr. Matthew Pollman, the company specializes in a fractional flow reserve (FFR) guidewire that facilitates accurate FFR measurements during coronary catheterization. This device is designed to improve maneuverability and handling, thereby enabling healthcare professionals to assess the physiological impact of coronary artery blockages more effectively. By minimizing the use of stents and reducing the risks associated with heart surgery, Guided Interventions aims to lower costs and improve patient outcomes in the treatment of cardiovascular conditions.
Rise Health, Inc., a healthcare services company, provides primary care solutions to help physician practices and other healthcare organizations in the United States. It allows patients to access primary care when they need; creates care experience for patients that provides the opportunity to engage with their primary care provider and manage their health; provides tools and support for physicians to manage the health of their patients; and leverages physicians' time and skills. The company also offers customers the tools, information, and capabilities to develop the infrastructure needed to participate in accountable care organizations and to support the precepts of a patient centered medical home. Rise Health, Inc. was formerly known as Optizend, Inc. The company was incorporated in 2009 and is based in Chicago, Illinois.
TVA Medical, Inc. is a medical device company based in Austin, Texas, focused on developing catheter-based solutions for end-stage renal disease and peripheral vascular diseases. Founded in 2009, the company specializes in innovative, minimally invasive therapies, notably through its everlinQ endoAVF system. This system facilitates the creation of an arteriovenous fistula using an endovascular approach, allowing for hemodialysis in patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. TVA Medical operates as a subsidiary of Becton, Dickinson and Company and has received funding from Santé Ventures.
Healthcare Highways was founded in 2010 by Michael Wilson who has spent the last 30+ years identifying and addressing the top challenges in the US healthcare system. With deep experience in creating PPO networks in Texas and Oklahoma, as well as a national TPA and Benefit Consulting firm, Michael and his team have been able to develop creative solutions for employers, providers and payers. Healthcare Highways is a forward thinking company with a singular mission: lower the cost of health care for members, providers and employers. They are not a reactive healthcare company; instead, they look five years ahead and design solutions that meet current and near-term challenges. They understand that change is extremely difficult and confusing for consumers and employers. Their objective is to drive positive, meaningful change, smoothing the transition to where they are headed as an industry, without sacrificing the quality of care that Americans expect and deserve.
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
Spinal Restoration, Inc. is a company focused on developing early intervention and minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it has created the Biostat System, which is designed to address chronic discogenic pain caused by internal disc disruptions. This system includes a resorbable biologic compound known as BIOSTAT BIOLOGX Fibrin Sealant, which acts as a tissue sealant, and a proprietary delivery device that administers the biologic directly to the intervertebral disc. The Biostat System aims to provide an effective treatment option for the significant population of adults—approximately four million—suffering from chronic low back pain.
BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
Spinal Restoration, Inc. is a company focused on developing early intervention and minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it has created the Biostat System, which is designed to address chronic discogenic pain caused by internal disc disruptions. This system includes a resorbable biologic compound known as BIOSTAT BIOLOGX Fibrin Sealant, which acts as a tissue sealant, and a proprietary delivery device that administers the biologic directly to the intervertebral disc. The Biostat System aims to provide an effective treatment option for the significant population of adults—approximately four million—suffering from chronic low back pain.
Rex Bionics Plc is engaged in the research and development, manufacture, and commercialization of robotic devices designed to provide physiotherapy to and improve the physical and psychological well-being of people with mobility impairment as a result of spinal cord injury or other neurological trauma, such as stroke or traumatic brain injury, or neurodegenerative disease. The Company develops and commercializes ReX, the hands-free, self-supporting, independently controlled robotic walking device for use in the rehabilitation of people with major mobility impairment. The Company offers two principal products: ReX and ReX P (Personal), which are targeted respectively at the professional neuro-rehabilitation clinic and personal homecare markets. The Company utilizes RAPPER II, which is an open label, single arm, non-randomized, non-comparative registry study of Robot-Assisted Physiotherapy Exercises with the REX Robot powered exercise system preventing unsupported patient ambulation.
AbVitro is a biotechnology company based in Boston, Massachusetts, focused on advancing treatments for diseases with immune-related components. The company utilizes high-throughput genomic sequencing to analyze millions of tumor and blood cells, aiming to identify new antigen targets and T-cell receptors for cancer immunotherapies. AbVitro's mission centers on leveraging the human immune system to uncover potential therapeutic targets or biomarkers while discovering fully human antibody binders and T cell receptors to address unmet medical needs in various diseases.
LumaTherm
Series A in 2012
LumaTherm, Inc.
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
ChanRx Corp. intends to develop and market small molecule pharmaceuticals to treat atrial fibrillation, a common arrhythmia that can cause heart attacks and strokes. The company was founded in 2008 and is based in Cleveland, Ohio.
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Millipede develops a catheter-based solution to treat mitral and tricuspid regurgitation, restoring health and expanding options for physicians, and global patients.
Explorys provides a secure cloud-computing platform specialized for the healthcare industry. We empower our customers to accelerate research and product development, while enabling critical measurement for healthcare reform, performance management and protocol safety.
Explorys provides a secure cloud-computing platform specialized for the healthcare industry. We empower our customers to accelerate research and product development, while enabling critical measurement for healthcare reform, performance management and protocol safety.
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
TVA Medical, Inc. is a medical device company based in Austin, Texas, focused on developing catheter-based solutions for end-stage renal disease and peripheral vascular diseases. Founded in 2009, the company specializes in innovative, minimally invasive therapies, notably through its everlinQ endoAVF system. This system facilitates the creation of an arteriovenous fistula using an endovascular approach, allowing for hemodialysis in patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. TVA Medical operates as a subsidiary of Becton, Dickinson and Company and has received funding from Santé Ventures.
Terapio Corporation is a biopharmaceutical company founded in 2005 and based in Austin, Texas. The company specializes in developing therapeutics that utilize the transport protein RLIP76, which plays a crucial role in moving free-radical toxins out of cells, thereby preventing significant cellular damage. Terapio's pipeline includes therapies that enhance the availability of RLIP76 in normal cells, improving their ability to combat toxins from various sources, including chemical exposure and radiation. The therapeutics are designed as medical countermeasures, providing prophylactic and post-exposure treatment options for civilian, military, and first responder populations facing chemical and radiation threats.
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, specializing in the discovery and development of biologic therapeutics for cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create differentiated therapeutic compounds with unique mechanisms of action. Its lead drug candidate, MT-3724, is undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing MT-4019, which targets CD38, and has established collaborations with Takeda Pharmaceutical Company to advance CD38-targeted therapies for conditions like multiple myeloma, as well as with Vertex Pharmaceuticals to enhance hematopoietic stem cell transplant processes. The company’s pipeline also includes other candidates such as MT-6402, MT-8421, and MT-0169.
Rise Health, Inc., a healthcare services company, provides primary care solutions to help physician practices and other healthcare organizations in the United States. It allows patients to access primary care when they need; creates care experience for patients that provides the opportunity to engage with their primary care provider and manage their health; provides tools and support for physicians to manage the health of their patients; and leverages physicians' time and skills. The company also offers customers the tools, information, and capabilities to develop the infrastructure needed to participate in accountable care organizations and to support the precepts of a patient centered medical home. Rise Health, Inc. was formerly known as Optizend, Inc. The company was incorporated in 2009 and is based in Chicago, Illinois.
BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
Protein Discovery, Inc., a life sciences company, develops and commercializes sample preparation technologies that enable protein and peptide analysis using mass spectrometry. It provides Gelfree 8100, a fractionation system that partitions complex protein mixtures into liquid-phase molecular weight fractions; Passport 1200, a sample preparation system that enriches low molecular weight proteins and peptides, and removes matrix interferences for high-throughput quantification applications; and PPS Silent Surfactant, a protein preparation reagent that solubilizes membrane proteins and cleaves to eliminate detergent interference. The company also provides UPX universal protein extraction kit for detergent extraction of proteins from cells and tissues. It serves life science researchers and drug development scientists. The company markets its products through Agilent Technologies, as well as online in the United States and internationally. Protein Discovery, Inc. was founded as Qgenics Biosciences, Inc. in 2001 and changed its name to Protein Discovery, Inc. in April 2004. The company is based in Knoxville, Tennessee.
Spinal Restoration, Inc. is a company focused on developing early intervention and minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it has created the Biostat System, which is designed to address chronic discogenic pain caused by internal disc disruptions. This system includes a resorbable biologic compound known as BIOSTAT BIOLOGX Fibrin Sealant, which acts as a tissue sealant, and a proprietary delivery device that administers the biologic directly to the intervertebral disc. The Biostat System aims to provide an effective treatment option for the significant population of adults—approximately four million—suffering from chronic low back pain.